A Study to Investigate Leramistat in Patients With IPF

Summary

To compare the effect of daily oral dosing of leramistat over 12 weeks with placebo in participants aged 40 years or older with idiopathic pulmonary fibrosis (IPF).

Timeline

Start

2023-08-30

Primary completion

2024-02-27

Completion

2024-03-14

Outcome

Outcome not reported

Stopped (Enrollment): “Due to slow initial recruitment and a lack of confidence in our ability to complete recruitment within the forecasted timeframe.”

Drugs

Indications